<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906397</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 24216, 826247</org_study_id>
    <nct_id>NCT02906397</nct_id>
    <nct_alias>NCT03081377</nct_alias>
  </id_info>
  <brief_title>Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>A Pilot Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and tolerability of galunisertib when combined with Stereotactic Body
      Radiotherapy (SBRT) (hypofractionated radiation).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety based upon standard laboratory and clinical adverse event monitoring</measure>
    <time_frame>Cycle 1 Day 15 through date of progression assessed up to 90 months</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) who are receiving the combination of galunisertib plus SBRT as compared to the PFS of Galunisertib alone in historical controls.</measure>
    <time_frame>Cycle 1 Day 15 through date of progression assessed up to 90 months</time_frame>
    <description>From Cycle 1 Day 1 to progression of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Cycle 3 Day 1 and every 8 weeks thereafter up to 90 months</time_frame>
    <description>by conventional CT and MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Cycle 1 Day 1 to death due to any cause or last patient contact alive up to 90 months</time_frame>
    <description>start of treatment to death due to any cause or last patient contact alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition of TGF-β signaling by intervention as evidenced by downstream changes in this pathway</measure>
    <time_frame>Cycle 1 Day 15 through date of progression assessed up to 90 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Promotion of anti-tumor immunity with addition of intervention to SBRT</measure>
    <time_frame>Cycle 1 Day 15 through date of progression assessed up to 90 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>ADVANCED HEPATOCELLULAR CARCINOMA (HCC)</condition>
  <arm_group>
    <arm_group_label>Experimental: Galunisertib/SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galunisertib (LY2157299) 150mg by mouth twice a day on days 1-14 of 28 day cycles SBRT 18Gy, delivered in one fraction between Cycle 1 D15 and D28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galunisertib 150mg by mouth twice a day</intervention_name>
    <description>on days 1-14 of 28 day cycles</description>
    <arm_group_label>Experimental: Galunisertib/SBRT</arm_group_label>
    <other_name>LY2157299</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy (SBRT)</intervention_name>
    <description>18GY delivered in one fraction between C1D15 and C1D28</description>
    <arm_group_label>Experimental: Galunisertib/SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically confirmed hepatocellular carcinoma (HCC) that is
             inoperable (where surgery is not indicated due to disease extension, co-morbidities or
             other technical reasons)

          -  ≥18 years of age and ability to understand and the willingness to sign a written
             informed consent document. A legally authorized representative signature in the event
             that the subject is not able to sign themselves is permitted.

          -  Patients must have either not been eligible for sorafenib therapy, have failed
             sorafenib therapy, have discontinued sorafenib therapy due to intolerable toxicity or
             have refused sorafenib

          -  ECOG performance status ≤2

          -  Childs Pugh score of ≤7

          -  Life expectancy of at least 12 weeks

          -  Must be able to swallow tablets

          -  Must be willing to comply with protocol procedures (including completion of diaries
             and outcome measures)

          -  Local or loco-regional therapy (ie surgery, radiation therapy, hepatic arterial
             embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol
             injection or cryoablation) must have been completed ≥4 weeks prior to enrollment

          -  Must be willing to undergo a pretreatment biopsy

          -  A history of prior radiotherapy is permitted, as long as the prior radiated site is
             not overlapping with the site of planned SBRT

          -  Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors
             (RECIST) version 1.1

          -  An index lesion measuring between 1cm-10cm that is amenable to hypofractionated
             radiation therapy at the discretion of the treating radiation oncologist

          -  Women of childbearing potential must have a negative serum pregnancy test performed at
             screening

          -  Subjects must use an approved contraceptive method (for example, intrauterine device,
             birth control pills or barrier device) which has an expected failure rate of &lt;1%, if
             appropriate for at least 3 months after the last dose of galunisertib.

        Patients who are HIV-positive are eligible if:

          -  CD4+ cell count is greater or equal to 250cells/mm3.

          -  If patient is on retroviral therapy, there must be minimal interactions or
             -overlapping toxicity of the antiretroviral therapy with the experimental cancer
             treatment.

          -  No history of non-malignancy AIDS defining conditions other than low CD4+ count.

          -  Probable long-term survival with HIV if cancer were not present.

          -  Must have adequate organ and hematopoietic function as defined below:

        Laboratory Test Required Value Absolute neutrophil count ≥1.5 x 10^9/L Platelet count ≥100
        x 10^9/L Hemoglobin ≥9.0 x 10^9/L Alanine transaminase ≤2.5 x ULN Aspartate
        aminotransferase ≤2.5 x ULN Serum creatinine or CrCl ≤2.0 x ULN Total Bilirubin ≤1.5 x ULN

        Exclusion Criteria:

          -  Any history of a serious medical or psychiatric condition that would prevent the
             patient from signing the informed consent form

          -  Pregnant or breastfeeding women.

          -  Use of any other chemotherapy, radiotherapy or experimental drug within 4 weeks prior
             to first study treatment date

          -  A history of radiotherapy that, in the opinion of the investigator, would render SBRT
             unsafe to administer

          -  Those who have not recovered from adverse events ≤ grade 1 secondary to therapy
             administered &gt;4 weeks prior to first study treatment date, with the exception of
             stable grade 2 neuropathy

          -  Subjects may not receive concomitant anticancer agents. Antiviral agents aimed at
             treating infectious hepatitis are permitted

          -  History of or suspected hypersensitivity to radiation or to galunisertib

          -  Uncontrolled ascites

          -  Subjects with a history of or evidence of cardiac disease during screening, defined as
             any one of the following: myocardial infarction within 6 months prior to study entry,
             unstable angina pectoris, New York Heart Association Class III/IV congestive heart
             failure, uncontrolled hypertension.

          -  Subjects with a documented major ECG abnormalities (not responding to medical
             treatments) or not clinically stable for at least 6 months.

          -  Subjects with major abnormalities documented by ECHO with Doppler (for example,
             moderate or severe heart valve function defect) that is not stable for at least 6
             months.. Note: Left ventricular [LV] ejection fraction &lt;50% is allowed only if
             clinically stable for at least 6 months (evaluation based on the institutional lower
             limit of normal).

          -  Subjects with a predisposition toward developing aneurysms of the ascending aorta or
             aortic stress including a family history of aneurysms, Marfan Syndrome, Ehlers Danlos
             Type IV, bicuspid aortic valve or evidence of damage to the large vessels of the heart
             documented by previously obtained or screening CT scan/MRI

          -  Subjects with uncontrolled brain metastases. Subjects with brain metastases must have
             stable neurological status following local therapy (surgery or radiation) for at least
             4 weeks prior to first study treatment and must be off steroids

          -  Any concurrent condition requiring the continued or anticipated use of systemic
             steroids beyond physiologic replacement dosing (excluding non-systemic inhaled,
             topical skin and/or eye drop-containing corticosteroids) or immunosuppressive therapy
             (excludes low-dose methotrexate). All other systemic corticosteroids above physiologic
             replacement dosing must be discontinued at least 4 weeks prior to first study
             treatment

          -  Active drug or alcohol use or dependence as documented in the chart that, in the
             opinion of the investigator, would interfere with adherence to study requirements

          -  A second primary malignancy that, in the judgment of the investigator, may affect the
             interpretation of results

          -  Prior malignancies. Patients with carcinoma in-situ of any origin and patients with
             prior malignancies who are in remission and whose likelihood of recurrence is very low
             (such as basal cell carcinoma) as judged by the Lilly clinical research physician
             (CRP), are eligible.

          -  Any illness or condition that in the opinion of the investigator may affect the safety
             of the subject or the evaluation of any study endpoint

          -  Any other conditions judged by the investigator that would limit the evaluation of the
             subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Reiss Binder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UPenn Office of Clinical Research</last_name>
    <phone>215-662-4484</phone>
    <email>psom-ocr@pobox.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Reiss Binder, MD</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>Kim Reiss Binder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2016</study_first_submitted>
  <study_first_submitted_qc>September 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

